Brainstorm Cell Therapeutics raises $1M in private placement, increases share pool by 5.5M

at the first closing and an additional $875,000 on up to seven additional closings. The final closing must be no later than Septembner 25, 2026. The per share purchase price is $0.60 and the per Pre-Funded Warrant purchase price is $0.60 less $0.0005, and each Pre-Funded Warrant has an exercise price of $0.00005 per share. The Investor may elect to receive

The Company will also issue to the investors common stock purchase warrants (the " Common Warrants ," and together with the shares of Common Stock and Pre-Funded Warrants sold, the " Securities ") exercisable for a number of shares equal to 120% of the total number of shares and Pre-Funded Warrants purchased by the Investor, with an exercise price of $1.00 per share, subject to adjustment.

On February 24, 2026, Brainstorm Cell Therapeutics Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with an accredited investor (the “ Investor ”), pursuant to which the Company agreed to sell, in a private placement, shares of its common stock, par value $0.00005 per share (the “ Common Stock ”), and, in lieu of shares as elected by an investor, pre-funded warrants to purchase Common Stock (the “ Pre-Funded Warrants ). The transaction will occur in up to eight closings. The aggregate subscription amount under the Purchase Agreement is $1,000,000, consisting of $125,000 at the first closing and an additional $875,000 on up to seven additional closings.